Drug Profile


Alternative Names: anti-HPV-16 E6 TCR; HPV-16 E6 TCR gene therapy

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer

Most Recent Events

  • 03 Oct 2017 Gilead Sciences acquired Kite Pharma
  • 29 Jun 2017 National Cancer Institute plans a phase I trial for Cervical intraepithelial neoplasia in USA (NCT03197025)
  • 02 Jun 2017 Adverse events and efficacy data from a phase II trial in HPV-associated Anal cancer, Cervical cancer, Oropharyngeal cancer, Penile cancer, Vulvovaginal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top